Has Claudio Levin received payments from drug or device companies?

Yes. Drug and device makers reported $2,104 in general payments to Claudio Levin across 114 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Claudio Levin did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Claudio Levin come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Claudio Levin

Internal Medicine · Reisterstown, MDNPI 1356398051

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 114 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 11.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,310 and has fallen 98.8% since, to $16 in 2023.

$2,104in general payments, 2019–2025

Across 114 payments — averaging $18.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$242
Novo Nordisk$236
Merck$204
Amarin Pharma, Inc.$198
Pfizer$182
Amgen$182
plus $860 from 16 others

What the payments were for

Food & beverage$2,104100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	16	$242
Novo Nordisk	11	$236
Merck	10	$204
Amarin Pharma, Inc.	6	$198
Pfizer	7	$182
Amgen	9	$182
AbbVie(2 entities)	8	$147
Boehringer Ingelheim	7	$119
Lilly USA, LLC	6	$95
Astellas Pharma US Inc	6	$86
Sanofi-aventis U.S. LLC	6	$83
Kowa Pharmaceuticals America, Inc.	5	$63
Johnson & Johnson	3	$48
Hikma Pharmaceuticals USA	2	$35
GSK	2	$34
Novartis	2	$32
Daiichi Sankyo Inc.	2	$28
E.r. Squibb & Sons, L.L.C.	2	$23
Alnylam Pharmaceuticals Inc.	1	$20
Sanofi Pasteur Inc.	1	$18
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	1	$17
Abbott	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

PREVNAR - 13$120
Vascepa$109

How this compares

$2,104 in reported general payments places this provider in the 80th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland →

Other internal medicine in Reisterstown

Marianne MannHighland$2.1M
Param DedhiaBaltimore$636K
Curtis RosebraughAshton$418K
Mark CorriereColumbia$402K
Gregory PokrywkaTowson$377K
Shawn DhillonBaltimore$227K
Brian HarveyAnnapolis$220K
Jeremy SugarmanBaltimore$210K
Florence HounPotomac$161K
Matthew MintzBethesda$135K

See the full list for Maryland →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →